Recent Quotes (30 days)

You have no recent quotes
chg | %

Takeda Pharmaceutical Co Ltd news

   Watch this stock
Showing stories 1 - 10 of about 121   

Articles published

4502 4,927.50 0.00 (0.00%)
price chart
Takeda appoints Sanofi's Andrew Plump to lead global R&D
TOKYO (Reuters) - Takeda Pharmaceutical Co Ltd said on Thursday it had appointed Andrew Plump as chief medical and scientific officer to lead its global research and development operations.
Related articles »  
Takeda, Lilly Jury Awards $9 Billion Over Actos Risks
Takeda Pharmaceutical Co. (4502) and Eli Lilly & Co. (LLY) were ordered to pay a combined $9 billion in punitive damages after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S.
Japan drugmaker Takeda to fight $6 billion damages awarded by US jury  Yahoo News
Takeda ordered to pay record $6bn over diabetes drug claim  Financial Times
Related articles »  
Wipro bags Rs 2400 crore Takeda Pharma deal
BANGALORE: Wipro has won an over $400 million (Rs 2,400 crore) deal from Takeda Pharma under which the former will develop and support IT requirements of the largest Japanese pharmaceutical company. The multi-year deal, described as a "strategic ...
Takeda Pharmaceuticals Partners with Wipro to Enable a Global "as-a ...  MarketWatch
Wipro bags IT contract from Japan's Takeda Pharmaceuticals  Business Standard
Related articles »  
BioMotiv and Takeda Pharmaceutical Company Enter into Strategic Partnership
CLEVELAND & OSAKA, Japan, Sep 25, 2014 (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (�Takeda�) and BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development, jointly ...
Related articles »  
Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety ...
WASHINGTON and OSAKA, Japan, March 27, 2014 /CNW/ - Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs.
Related articles »  
Narrower of Possible Claim Constructions Prevails - Takeda Pharmaceutical Co ...
Takeda Pharmaceutical Co. Ltd. v. Zydus Pharma USA, Inc., Case No. 13-1406 (Fed. Cir., Feb. 20, 2014) (Prost, J.). Takeda Pharmaceutical and several related entities own patents claiming the formulation for the brand-name drug Prevacid� SolutabTM, ...
Takeda Pharmaceutical to stay Japan-based while growing on global basis, new ...
The inauguration in June of Christophe Weber as president of Takeda Pharmaceutical Co. invited opposition from a group of its former executives and members of its founding family, but the Frenchman says Takeda will remain �Japanese-based� under his ...
Related articles »  
Takeda's ixazomib a Breakthrough Therapy for amyloidosis
The FDA designates Takeda Pharmaceutical Company's (OTCPK:TKPHF) (OTCPK:TKPYY) investigational oral proteasome inhibitor, ixazomib, a Breakthrough Therapy for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis.
Takeda: FDA Grants Breakthrough Therapy Status To Ixazomib  RTT News
Related articles »  
Stocks to Track -Silvercorp Metals Inc. (USA)(NYSE:SVM), Takeda ...
Takeda Pharmaceutical Co Ltd (ADR)(OTCMKTS:TKPYY)was moving upward during the previous trading session. The company traded with the surge 0.95% and closed at $21.21, after gaining total volume of 37,496.00 shares.
Takeda Pharmaceutical (TKPHF) Q2 2014 Results - Earnings Call Transcript ...
Thank you very much for your participation in the conference call of the First Quarter Financial Results for Fiscal Year 2014 of Takeda Pharmaceutical Company Limited. My name is Christopher Hohman, Senior Vice President of the Corporate ...